Clyde Biosciences secures new investment
Clyde Biosciences Ltd. has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund.
Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round along with Glasgow University Holdings, Ltd. Clyde Biosciences, a spin-out company from the University of Glasgow, has developed a pioneering technology to evaluate drug toxicity for pharmaceutical and biotechnology companies.
The company utilises induced pluripotent stem cells (iPSCs) to mimic cardiomyocyte activity and measure action potential features which are important indicators of cardiotoxicity. Changes in action potential are visualised using voltage-sensitive dyes (VSDs) and are measured and analysed on tissue culture plates using Clyde’s proprietary software.
CellOPTIQ is currently being evaluated by the US Food & Drug Administration (FDA) through its Comprehensive In Vitro Proarrhythmia (“CiPA”) programme; an initiative to facilitate the adoption of a new paradigm for cardiotoxicity screening of clinical candidates.
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.